Shots:

• The P-III CHRONOS-3 study involves assessing of Aliqopa + rituximab vs PBO + rituximab in 458 patients with relapsed indolent NHL who have received at least one or more lines of prior rituximab-containing treatment
• The P-II study met its 1EP of prolonged PFS- safety is consistent with previously published data on the individual components of the combination- no new safety signals were identified
• Aliqopa is a PI3K inhibitor with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms expressed in malignant B cells and is an approved treatment for patients with relapsed FL prior treated with two systemic therapies
  
    Ref: Businesswire Image: Business Insider